BioTelemetry (BEAT) PT Set at $95.00 by Sidoti

BioTelemetry (NASDAQ:BEAT) received a $95.00 price target from research analysts at Sidoti in a report issued on Tuesday, February 5th. The firm currently has a “buy” rating on the medical research company’s stock. Sidoti’s price objective would indicate a potential upside of 29.66% from the stock’s current price.

Several other equities analysts also recently commented on the company. BidaskClub downgraded BioTelemetry from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 18th. Zacks Investment Research cut BioTelemetry from a “buy” rating to a “hold” rating in a research note on Monday, February 4th. Raymond James cut their target price on BioTelemetry from $66.00 to $64.00 and set an “outperform” rating for the company in a research note on Wednesday, October 31st. Finally, ValuEngine upgraded BioTelemetry from a “buy” rating to a “strong-buy” rating in a report on Monday, February 4th. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $75.67.

BEAT stock traded down $1.45 during trading on Tuesday, hitting $73.27. The stock had a trading volume of 1,112,078 shares, compared to its average volume of 652,799. BioTelemetry has a 1-year low of $29.85 and a 1-year high of $80.92. The company has a market capitalization of $2.21 billion, a price-to-earnings ratio of 37.77, a PEG ratio of 3.73 and a beta of 1.75. The company has a current ratio of 2.68, a quick ratio of 2.50 and a debt-to-equity ratio of 0.66.

BioTelemetry (NASDAQ:BEAT) last issued its quarterly earnings data on Thursday, February 21st. The medical research company reported $0.56 EPS for the quarter, beating the Zacks’ consensus estimate of $0.43 by $0.13. The business had revenue of $103.60 million for the quarter, compared to analyst estimates of $102.84 million. BioTelemetry had a return on equity of 25.25% and a net margin of 10.72%. The firm’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.32 EPS. As a group, research analysts predict that BioTelemetry will post 1.86 earnings per share for the current year.

In other news, VP Heather C. Getz sold 93,383 shares of the business’s stock in a transaction on Tuesday, January 29th. The shares were sold at an average price of $70.06, for a total transaction of $6,542,412.98. Following the completion of the transaction, the vice president now directly owns 119,085 shares in the company, valued at approximately $8,343,095.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Heather C. Getz sold 10,590 shares of the business’s stock in a transaction on Friday, February 1st. The shares were sold at an average price of $70.41, for a total transaction of $745,641.90. Following the transaction, the vice president now owns 80,661 shares of the company’s stock, valued at $5,679,341.01. The disclosure for this sale can be found here. Insiders sold a total of 177,198 shares of company stock worth $12,419,736 in the last ninety days. 8.30% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Miles Capital Inc. grew its position in BioTelemetry by 1.9% in the fourth quarter. Miles Capital Inc. now owns 8,006 shares of the medical research company’s stock worth $478,000 after acquiring an additional 152 shares in the last quarter. State of Alaska Department of Revenue lifted its stake in shares of BioTelemetry by 2.3% in the 4th quarter. State of Alaska Department of Revenue now owns 11,132 shares of the medical research company’s stock valued at $664,000 after purchasing an additional 245 shares during the period. Resources Investment Advisors Inc. lifted its stake in shares of BioTelemetry by 2.1% in the 4th quarter. Resources Investment Advisors Inc. now owns 12,299 shares of the medical research company’s stock valued at $734,000 after purchasing an additional 251 shares during the period. Piedmont Investment Advisors Inc. lifted its stake in shares of BioTelemetry by 5.2% in the 4th quarter. Piedmont Investment Advisors Inc. now owns 7,919 shares of the medical research company’s stock valued at $473,000 after purchasing an additional 388 shares during the period. Finally, Bank of Montreal Can lifted its stake in shares of BioTelemetry by 29.1% in the 4th quarter. Bank of Montreal Can now owns 1,924 shares of the medical research company’s stock valued at $115,000 after purchasing an additional 434 shares during the period. Hedge funds and other institutional investors own 87.43% of the company’s stock.

About BioTelemetry

BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.

Further Reading: Earnings Per Share

Analyst Recommendations for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.